Dr. Edward Libby provides an update on multiple myeloma treatment at ASH 2013. Dr. Libby is most excited about the research that's going into monoclonal antibodies for treatment of multiple myeloma. Monoclonal antibodies are relatively non-toxic, but have added to the quality of response in treatment of other diseases such as lymphoma. New trials are being conducted with Daratumumab in combination with Revlimid and Dexamethasone, with remarkable results for patients with relapsed and refractory multiple myeloma. Our understanding of smoldering myeloma is rapidly increasing, and positive results have been seen from beginning treatment at this earlier stage. However, Dr. Libby cautions that there is still much to learn and treatment of smoldering myeloma is not ready for the general world of oncology.